Pliva Lachema

Pliva-Lachema is a pharmaceutical company based in Brno, Czech Republic, specializing in the development and manufacture of oncology drugs and high-potency active pharmaceutical ingredients. Originally founded in 1951 as the state-owned enterprise Lachema, it became a pioneer in the production of platinum-based cytostatics such as cisplatin. The company was acquired by the Croatian Pliva Group in 1999 and subsequently integrated into Teva Pharmaceutical Industries following Teva's acquisition of Pliva's parent company. Today, the facility operates as a key manufacturing and R&D hub within Teva's global network, focusing on complex generics and injectable oncology treatments. It maintains high standards of GMP compliance for the production of both APIs and finished dosage forms. The site is particularly noted for its expertise in handling hazardous substances and high-containment manufacturing processes.